Ironwood Pharmaceuticals (NASDAQ: IRWD)
At Ironwood Pharmaceuticals, we are committed to advancing the treatment of GI diseases and redefining the standard of care for GI patients. As a pioneer and champion in the development of a market-leading therapy for IBS-C and CIC, we are singularly focused on advancing the treatment of GI diseases and continue to challenge what has been done before to shape what the future holds.
So, we named ourselves after the Ironwood tree, which can live for thousands of years in the harshest desert, creating a shaded microclimate in which life thrives. Iron, like science, is undeniable and strong. Wood, like artistry and humanity, is flexible, resilient and versatile. The two words together represent our passion for making a positive impact on the health – and lives- of GI patients, their families and communities.
Ironwood was founded in 1998 and is headquartered in Boston. For more information, please visit www.ironwoodpharma.com or www.twitter.com/ironwoodpharma; information that may be important to investors will be routinely posted in both these locations.